The stock of Alcobra Ltd (NASDAQ:ADHD) hit a new 52-week low and has $3.63 target or 13.00% below today’s $4.17 share price. The 8 months bearish chart indicates high risk for the $108.96 million company. The 1-year low was reported on Mar, 16 by Barchart.com. If the $3.63 price target is reached, the company will be worth $14.16 million less. The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock is down 4.79% or $0.21 after the news, hitting $4.17 per share. About 55,799 shares traded hands. Alcobra Ltd (NASDAQ:ADHD) has declined 43.77% since August 10, 2015 and is downtrending. It has underperformed by 39.58% the S&P500.
Analysts await Alcobra Ltd (NASDAQ:ADHD) to reports earnings on May, 4. They expect $-0.22 earnings per share, up 15.38% or $0.04 from last year’s $-0.26 per share. After $-0.20 actual earnings per share reported by Alcobra Ltd for the previous quarter, Wall Street now forecasts 10.00% negative EPS growth.
Out of 6 analysts covering Alcobra (NASDAQ:ADHD), 4 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alcobra was the topic in 6 analyst reports since August 9, 2015 according to StockzIntelligence Inc.
According to Zacks Investment Research, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.”
Alcobra Ltd - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.